Arcutis Biotherapeutics Announces Inducement Grants in Compliance with Nasdaq Rules

WESTLAKE VILLAGE, Calif. – Arcutis Biotherapeutics, Inc. ARQT, a pioneering company in the field of immuno-dermatology, declared the issuance of inducement grants totaling 90,500 restricted stock units. This strategic move is in line with Nasdaq Listing Rule 5635(c)(4), underscoring the company's commitment to attracting and retaining top-tier talent through equity-based incentives.

Understanding the Inducement Grants

As part of the effort to incentivize new employees and align their interests with those of shareholders, Arcutis has granted restricted stock units to recently hired employees. The aim of these grants is to promote long-term dedication and contribute to the future success of the company which is making strides in the treatment of dermatological conditions.

Arcutis Biotherapeutics: At the Forefront of Dermatology Innovation

Incorporated in Westlake Village, California, Arcutis Biotherapeutics, Inc. ARQT is a biopharmaceutical company primarily focused on leveraging its expertise to develop breakthrough treatments for skin diseases. The company's deep commitment to research and development is central to its aim in addressing unmet needs in the field of dermatology, bolstering its early commercial-stage profile. With these recent inducement grants and its ongoing product development efforts, Arcutis is poised to create a lasting impact in healthcare.

Arcutis, Biotherapeutics, Inducement